Non-viral focus Anjarium specializes in non-viral gene therapies and DNA construct technologies, presenting a compelling opportunity to position compatibility with customers seeking safer, scalable delivery alternatives to viral vectors.

Early-stage traction With funding of $60M and leadership hires in 2022, there is momentum for partnerships and co-development deals leveraging their enzymatic cell-free platform to accelerate discovery and manufacturing timelines.

Swiss biotech hub Headquartered in Switzerland with a focused niche in genetic medicines, Anjarium can be targeted for collaborations with European biotechs and academic groups seeking EU-based, compliant manufacturing and research tools.

Broad application scope Their platform supports DNA constructs for AAV, mRNA, and Lentivirus applications, enabling cross-sell opportunities to customers exploring multiple gene therapy modalities and construct customization needs.

Strategic leadership network Recent additions to the board and executive team (CTO and independent directors) indicate an openness to strategic partnerships, licensing, and advisory relationships that can be unlocked for business development conversations.